The committee voted yes — and overruled its own scientists to do it

We said we'd report the votes, not the vibes. The hearing is underway, results are still coming in, and the headline is already clear.

What is an FDA advisory committee?

It's a panel of outside experts — clinicians, scientists, sometimes patient and industry representatives — that the FDA convenes to review evidence on a specific question and vote a recommendation. The Pharmacy Compounding Advisory Committee (PCAC) is the one handling peptides.

Three things worth knowing, all of which matter this week. The vote is non-binding — it's advice, and the FDA makes the final call (it usually follows, but not always). Members are appointed, which means the composition of a panel can shape its conclusions. And the agency's own staff scientists produce a separate review, which the committee can agree with or disregard. When those two diverge, that's news — and this week, they diverged.

The votes — and the scientists they overruled

On day one, the committee voted 8–6 with one abstention in favor of adding BPC-157 to the 503A compounding list — then voted identically, 8–6 with one abstention, for KPV. (Each peptide got two votes, covering its free-base and acetate forms.) Votes on TB-500 and MOTS-c followed Thursday afternoon, with Emideltide (DSIP), Semax and Epitalon scheduled for Friday.

The part that matters most: they overruled their own scientists. FDA career reviewers submitted briefing documents opposing all seven peptides, applying the formal four-factor test. Their objections were specific: no human clinical evidence at all for KPV, TB-500 and MOTS-c; small, poorly-controlled studies for BPC-157, Emideltide and Semax; plus immunogenicity concerns, adverse-event reports on file for BPC-157, and World Anti-Doping Agency prohibited status for MOTS-c and TB-500. The committee heard that analysis and voted yes anyway. Narrowly — 8–6 is not a rout — but yes.

The context you need to judge this fairly. Two things are true at once, and most coverage will give you only one.

First, the criticism: the panel was recently overhauled, and reporting notes that many of the new members have ties to the peptide industry — operating clinics, pharmacies, or businesses that promote peptides — with additional voting members added just this week. HHS Secretary Robert F. Kennedy Jr., who oversees the FDA and has said he uses peptides himself, has publicly pushed for easier access.

Second, the steelman — because the access argument isn't stupid: hundreds of thousands of people are already using these compounds, overwhelmingly from unregulated gray-market sources with no purity testing, no dosing standards, and no physician involved. A legal compounding pathway means pharmacy-grade material and a prescriber in the loop. That's a genuine harm-reduction case, and roughly 1,860 docket comments — most favoring inclusion — reflect real people who feel it.

Here's the distinction we'd ask you to hold onto: that harm-reduction argument is about safer access to a thing people already take. It is not evidence that the thing works. Both can be true. The danger is that a "yes" vote gets marketed to you as scientific validation, when what actually happened is a policy judgment about access — made over the objection of the scientists who assessed the data.

And the timeline hasn't changed. These votes are recommendations. The FDA still decides, then runs formal rulemaking that typically takes 6 to 18 months. Nothing hits a pharmacy shelf this summer.

The evidence didn't change this week. The room did.

That's worth sitting with, because it's the cleanest possible illustration of something we say constantly here: regulatory status and scientific evidence are different axes.

Nothing about BPC-157's human data improved between Monday and Thursday. There was no new trial, no published result, no fresh safety database. What changed was who was in the seats and how they weighed the same information. If these peptides become legally compoundable in 2027, they will be exactly as studied as they are today — which, per the FDA's own review, means small and poorly-controlled studies at best, and for several of them, no human trials at all.

The keeper concept: "available at a pharmacy" is a legal status. "Proven to work" is a scientific status. This week is the clearest demonstration you will ever get that a compound can move on the first axis without moving an inch on the second. When the marketing starts — and it will start fast — that's the question to ask: did the evidence change, or did the rules?

So what should you actually do with this?

Expect a marketing surge. A favorable vote — even a narrow, advisory, not-yet-in-effect one — will be used as a credibility badge in clinic advertising and social media almost immediately. "FDA panel approved" will appear in copy where it doesn't belong. Now you know precisely what it means and what it doesn't.

Nothing about your decision framework changed. The peptides with the best evidence for midlife are still the FDA-approved ones (the GLP-1s, with the muscle-and-bone caveats we've covered) and topical GHK-Cu for skin. Collagen peptides remain a reasonable supplement-tier add-on. None of the seven voted on this week has human efficacy data that would change how you'd prioritize.

And the sequence still holds. Foundation first — sleep, protein, strength training. Then hormones, addressed properly with a clinician who knows your history. Then, and only then, peptides with real evidence behind them. A committee vote in Silver Spring doesn't reorder that list. Hormones are the floodlight; peptides are the spotlight; the room still has to be lit first.

One thing genuinely worth watching for you specifically: GHK-Cu — the copper peptide with actual relevance to midlife skin — is on the docket for the second PCAC meeting, expected before the end of February 2027, alongside Melanotan II, LL-37, Dihexa and PEG-MGF. Given what just happened, that meeting now looks a lot more consequential. We'll be there.

Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory details current as of writing and subject to change.

← All issues